视网膜分支静脉阻塞治疗研究现状

视网膜静脉阻塞（retinal vein occlusion，RVO）是继糖尿病性视网膜病变第二大视网膜血管类疾病，可分为视网膜中央静脉阻塞和视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）。BRVO的具体发病机制目前尚不明确，且发病率逐年升高。BRVO常发生黄斑水肿（macular edema，ME），反复的ME会导致永久的视力下降。传统的治疗包括黄斑区格栅样光凝和以曲安奈德、地塞米松为代表的糖皮质激素类药物，近年来，抗血管内皮生长因子类药物及玻璃体手术的发展已成为新的治疗方法。本文就BRVO的治疗进展作一简要综述。

Treatment research status of branch retinal vein occlusion

Retinal vein occlusion （RVO） is the second common retinal vascular disease after diabetic retinopathy，which is divided into central retinal vein occlusion and branch retinal vein occlusion （BRVO）.The current specific pathogenisis of BRVO is remain unclear and the incidence rate has been increases year by year.BRVO often causes macular edema （ME），and recurrent ME can lead to a permanent decline in vision.Traditional treatment includes grid laser photocoagulation and glucocorticoid drugs represented by traimcinolone and dexamethasone.In recent years，anti-vascular endothelial growth factor drugs and vitrectomy have developed，and become new treatment methods for BRVO.This paper will give a review on the recent advances in the treatment methods of BRVO.